BC008-1A / REMD Bio, Buchang Pharma - LARVOL DELTA

BC008-1A, a PD-1/TIGIT bispecific antibody, in recurrent CNS WHO grade 4 glioma: phase I safety and efficacy results (EANO 2026) - "BC008-1A demonstrated manageable safety and encouraging antitumor activity in recurrent CNS WHO grade 4 glioma. The rapid onset and durability of response support further clinical development; 900 mg appears suitable for priority evaluation in subsequent studies."

Bispecific • Clinical • P1 data • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • PD-1 • TIGIT

Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BC008-1A Injection for Recurrent CNS WHO G4 Glioma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

BC008-1A Injection for Recurrent CNS WHO G4 Glioma (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

New P1 trial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Phase I Study of BC008-1A Injection in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.

New P1 trial • Esophageal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, received IND clearance from NMPA for clinical trial (Yahoo Finance) - "Buchang Biopharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, recently received IND approval of BC008-1A from China NMPA for Phase 1 clinical trial. BC008-1A (NMPAIND number: CXSL2200315), a bispecific antibody drug co-targeting the immune checkpoints PD-1 and TIGIT, for treatment of patients with advanced solid tumors...Buchang Biopharmaceutical will be responsible for the Phase 1 trial in China for BC008-1A. During the development of BC008-1A bispecific antibody, by using the screening and evaluation system of GenScript ProBio's SMABody® (Single-Domain Antibody fused to Monoclonal Ab) platform, Buchang Biopharmaceutical collaborated with REMD Biotherapeutics developed and optimized the CMC process and completed several batches of clinical samples. The approval of BC008-1A for clinical development has demonstrated the feasibility and manufacturability of SMABody® bispecific antibody platform."

New P1 trial • Oncology • Solid Tumor